A biohacking channel walks through the latest retatrutide study results and gives his read on how strong the weight loss figures look.
Recap by typeshit. Full story at Iron Mike Biohacking.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Novo Nordisk also plans 26 obesity abstracts for ObesityWeek, November 14 to 17, including CagriSema analyses and real-world data on the Wegovy pill.
He argues Lilly's tirzepatide profits give it a big head start to pour billions back into research. This is an investor's opinion, not a forecast from Lilly.
Loading…